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Dear Editors,  
 
Ischemic-type biliary lesions (ITBLs) significantly reduce 
patient and graft survival rates. Research data regarding the 
causes of ITBL are rare. ITBLs is an important cause of 
post liver transplantation graft loss and patient death. The 
exact cause of this type of biliary complication remains un-
clear. To establish strategies for ITBL treatment or preven-
tion, the risk factors of ITBL must be elucidated. The objec-
tive of this single-center retrospective study was to investi-
gate the risk factors of ITBL in orthotopic liver transplanta-
tion (OLT) patients. 
ITBLs occur in liver transplant recipients with symptoms 
of biliary stenosis, expansion, biliary abscess formation, 
biliary disappearance, and liver dysfunction. The reasons 
for this occurrence remain unknown. However, some possi-
ble reasons have been proposed, such as hepatic artery 
thrombosis, antibody-mediated rejection, primary sclerosing 
cholangitis, or chronic rejection, which may cause similar 
symptoms but are not included as causes of ITBLs. 
In this retrospective study, 1,328 OLT patients with 
complete data who underwent liver transplantation between 
August 2007 and January 2014 at the Tianjin First Central 
Hospital Organ Transplant Center were considered for the 
study. In accordance with the definition of ITBL, we used 
the following exclusion criteria: (i) postoperative hepatic 
arterial thrombosis; (ii) ABO blood group incompatibility 
liver transplantation; (iii) a preoperative diagnosis of pri-
mary sclerosing cholangitis; (iv) patients with postoperative 
chronic rejection; and (v) a survival or follow-up time of <3 
months after transplantation. The data of 886 OLT patients 
were included in the study. 
The statistical calculations were performed with the 
SPSS 19 software (IBM, USA). In this study, P values of 
<0.05 were considered statistically significant. 
The data included the following primary disease statis-
tics: 530 cases of hepatitis B cirrhosis; 109 cases of hepatitis 
C cirrhosis; 33 cases of non-hepatitis malignant hepatic tu-
mor; 55 cases of alcoholic cirrhosis; 42 cases of primary 
biliary liver sclerosis; 33 cases of cryptogenic cirrhosis; 31 
cases of autoimmune hepatitis; 27 cases of retransplanta-
tion, 15 cases of congenital disease; two cases of 
Budd-Chiari syndrome; three cases of drug-induced liver 
disease; two cases of polycystic liver; and four cases of 
Wilson’s disease. 
The overall ITBL incidence in this group of patients was 
14.00% (124/886). 
The donor- and surgery-related risk factors are shown in 
Table 1. The risk factors include cold ischemic time, 
non-hepatic phase, amount of intraoperative red blood cells 
used, and the amount of intraoperative blood plasma used. 
The data were analyzed by using an independent sample t 
test. The classification data were analyzed with a 
cross-tabulation test. 
The SPSS 19 software (IBM company spss19, USA) was 
used in the multivariate analysis. All 886 cases were in-
cluded in the multivariate analysis by using a logistic re-
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Table 1  Donor, recipient and surgery-related risk factors 
Group Cases Non-ITBL ITBL Statistics P 
Cases, n 886 762 124 − − 
Donor factors − − − − − 
Donor age − 33.84±9.75 34.63±9.63 t=0.835 0.763 
Cold ischemia (min) − 486.88±210.41 572.98±174.53 t=4.320 0.000 
Graft weight (g) − 1003.64±293.38 1066.48±225.20 t=2.278 0.023 
Donor steatosis − − − − − 
None 790 680 110 χ2=0.67 0.712 
Mild <30% 82 71 11 − − 
Moderate 30%–60% 14 11 3 − − 
Storage solution − − − − − 
University of Wisconsin organ perfusion 
preservation solution 
788 673 115 χ2=2.21 0.092 
Histidine-tryptophan-ketoglutarate 98 89 9 − − 
Recipient factors − − − − − 
Recipient sex − − − − − 
Male 726 619 107 χ2=1.84 0.208 
Female 160 143 17 − − 
Recipient age − 48.03±15.69 51.14±9.12 t=1.936 0.053 
Blood type − − − χ2=5.860 0.119 
A 246 212 34 − − 
B 281 232 49 − − 
AB 112 96 16 − − 
O 247 222 25 − − 
Model of end-stage liver disease score − 16.54±8.66 16.64±9.55 t=0.109 0.914 
Child-Pugh − − − χ2=1.092 0.579 
A 232 201 31 − − 
B 363 307 56 − − 
C 291 254 37 − − 
Primary disease − − − χ2=4.088 0.770 
Hepatitis B virus 530 447 83 − − 
Hepatitis C virus 109 96 13 − − 
Hepatocellular carcinoma (Non-hepatitis) 33 30 3 − − 
Primary biliary liver sclerosis 42 36 6 − − 
Retransplantation 27 23 4 − − 
Autoimmune hepatitis 31 28 3 − − 
Alcoholic cirrhosis 55 50 5 − − 
Others 59 52 7 − − 
Surgery-related risk factors − − − − − 
Non-hepatic (min) − 47.44±15.06 53.98±22.59 t=4.139 0.000 
Red blood cells (unit) − 11.81±11.25 15.06±11.02 t=2.990 0.003 
Blood plasma (mL) − 2038.01±1195.92 2565.73±1053.98 t=4.629 0.000 
Cytomegalovirus infection − − − χ2=0.032 1.000 
Positive 27 4 12.90 − − 
Negative 735 120 14.04 − − 
Acute rejection − − − χ2=1.224 0.229 
Occurrence 9 − 25.00 − − 
Non-occurrence 753 121 13.85 − − 
 
gression model. All of the cases were divided into two 
groups according to the occurrence of ITBL as follows: the 
ITBL group (n=124) and the non-ITBL group (n=763). The 
following factors were analyzed: recipient age, model of 
end-stage liver disease (MELD) score, Child-Pugh classifi-
cation, cytomegalovirus (CMV) infection status, non-  
hepatic period, intraoperative red blood cells used, fresh- 
frozen plasma dosage, acute rejection, recipient sex, graft 
weight, fatty liver degree, and cold ischemic time. The re-
sults are shown in Supporting Information. The results 
showed a statistically significant difference between ITBL 
occurrence and cold ischemic time (P=0.000), the non-  
hepatic period (P=0.002), and the amount of intraoperative 
frozen plasma used (P=0.012). The cold ischemic time, 
non-hepatic period, and amount of intraoperative frozen 
plasma used were the independent risk factors of ITBL oc-
currence. 
The clinical data of the 886 liver transplant patients were 
analyzed in this study. The ITBL incidence was 14%. The 
reported incidence of ITBL ranged from 1.4% to 26% 
(Zhang et al., 2014). The donor age and cold ischemic time 
were reported to be significant risk factors of the occurrence 
of ITBL. ITBL occurs more frequently when the liver is 
preserved in a histidine-tryptophan-ketoglutarate organ 
perfusion preservation solution than in the University of 
Wisconsin organ perfusion preservation solution (Girometti 
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and Baccarani, 2013). Some researchers found that the pre-
surgical MELD and Child-Pugh scores of the recipients 
significantly affect the incidence of ITBL (Wang et al., 
2013). CMV infection status and immune factors such as 
the effect of acute rejection have been reported to be risk 
factors of ITBL (Wang et al., 2013; Frongillo et al., 2014). 
Two views have emerged regarding the factors that de-
termine the occurrence of ITBL after liver transplantation. 
First, the disease starts during the period in which the donor 
liver undergoes cold ischemia, warm ischemia, and reperfu-
sion injury; a latency period occurs until the results of bili-
ary disease are manifested (Boyko et al., 2014). Second, 
early postoperative immune factors invade the donor liver 
and repeatedly attack the biliary tract, and an ITBL gradu-
ally forms (Girometti and Baccarani, 2013). 
This study, as well as most studies in the literature, pre-
sents evidence that strongly supports the first hypothesis and 
the theory of damage during preservation (Frongillo et al., 
2014). Further research should focus on the mechanism of 
biliary tract disease that occurs during storage and on in-
traoperative findings. 
In this study, the multivariate analysis revealed that fatty 
liver and perfusion fluid types did not influence the inci-
dence of ITBL. However, cold ischemic time showed a sta-
tistically significant difference. Some studies have shown 
that >10 hours of cold storage time has a significant effect 
on the incidence of ITBL (Wang et al., 2013). Minimizing 
the cold ischemic time is probably advantageous to patients. 
However, given the severe shortage of donors, the risk of 
death during the waiting period must be considered as well. 
In recent years, the use of marginal donors, older donors, 
donor liver steatosis, donor livers with long cold storage 
time, low-perfusion donor livers, and grafts with hepatitis 
has increased. In particular, the use of marginal donor or-
gans has become controversial, and the task of ITBL pre-
vention has become more difficult. 
In this study, the non-hepatic period is an independent 
risk factor of ITBL, which is a relatively unique finding. 
Most studies have concluded that ITBL is not correlated 
with non-hepatic time, the amount of intraoperative red 
blood cells used, and plasma use, among other factors. By 
contrast, in our group of patients, a strong correlation was 
shown. The above-mentioned results reflect the increasing 
surgical difficulties that affect the occurrence of ITBL. 
These indicators are frequently concomitant with prolonged 
intraoperative graft ischemic time, severe hypotension, liver 
hypoperfusion, and delayed liver function recovery. Re-
search on the relationship between early graft function and 
intraoperative conditions to ITBL is rare (Boyko et al.,  
2014). To identify the effect of surgical factors on ITBL, 
surgeons should conduct further research on the relationship 
between intraoperative factors and ITBL. 
Plasma use during operation was found as a risk factor of 
ITBL occurrence. In the univariate analysis, we found that 
red blood cell use is also a risk factor. However, in the mul-
tivariate analysis, between the two factors, that which 
showed a relationship with ITBL occurrence was identified. 
Thus, plasma use during operation was the only independ-
ent risk factor identified. Difficulty in operating, poor pre-
operative liver function, and delayed donor function recov-
ery could lead to additional plasma use during operation. 
Altogether, these adverse factors could cause the develop-
ment of ITBL. 
This study shows that cold ischemic time, non-hepatic 
time, and the amount of intraoperative blood plasma used 
are the main risk factors of ITBL occurrence. These results 
show that ITBL closely correlates with liver cold preserva-
tion and surgical procedures. Efforts to clinically reduce the 
incidence of ITBL should focus more on shortening liver 
preservation and surgical times, and reducing blood loss by 
selecting a more experienced transplant surgery group to 
complete the operation. 
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